CNS Pharmaceuticals, Inc. Common Stock (CNSP) Stock Price

CNSPStock
$5.808.33%52W
Market Cap$8.48M
P/E
PEG Ratio
Div yield
Beta1.06

CNSP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)75.55%
Price vs S&P 500 (4W)14.11%
VGM Score63.83

CNSP Earnings Surprise History

Q2 25-6.42est. -9.60
Q3 25-5.76est. -6.63
Q4 25-10.15est. -5.09
Q1 26-7.30est. -5.37

CNSP Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CNSPCNS Pharmaceuticals, Inc. Common Stock
B$5.80
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About CNS Pharmaceuticals, Inc. Common Stock

CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing anticancer therapies for brain and central nervous system tumors. The company's lead candidate, Berubicin, is in development for glioblastoma, an aggressive form of primary brain cancer with limited treatment options. The company aims to address significant unmet medical needs in oncology.